Communiqués Celularity Inc.

Actions

CELU

US1511902041

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
1,600 ^USD	+15,94%		+15,94%	+44,14%

29/09	Celularity Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
29/09	Celularity Inc. annonce la nomination de Naveen Jain au conseil d’administration	CI

Communiqués

30/09	Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner	AQ
29/09	Celularity : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
29/09	Celularity Announces Naveen Jain to Join Board of Directors	AQ
24/09	Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements	AQ
27/08	Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform	BU
26/08	Celularity Provides Update Regarding Nasdaq Listing Compliance	AQ
04/06	Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies	AQ
03/06	Celularity Releases CEO Letter to Shareholders	AQ
03/06	Celularity Appoints Rick Gonzalez as Chief Commercial Officer	AQ
01/06	Celularity Receives Nasdaq Notice Regarding Form 10-Q	AQ
29/05	Celularity Receives Nasdaq Notice Regarding Form 10-Q	AQ
01/05	Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation	AQ
01/05	Celularity : Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K)	PU
27/04	NEXGEL Appoints Ian Blackman as Chief Financial Officer	AQ
21/04	NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment	AQ
21/04	Celularity Announces Closing of Transaction with NexGel	AQ
17/04	Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing	AQ
10/03	Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy	AQ
10/02	Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses	AQ
26/12	Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations	AQ
22/12	Celularity Announces Closing of Financing Transactions	AQ
18/12	Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision	AQ
30/10/25	Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care	AQ
14/10/25	Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease	AQ
03/09/25	Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance	AQ